AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth

What happened

AstraZeneca reported core earnings of $2.79 per share, beating the $2.59 consensus, while revenue rose 7% to $16.21 billion. Oncology grew 17% to $7.765 billion, offsetting declines in Farxiga and Brilinta.

Confirmed

Global impact / market context

Stronger profit and sales than expected show AstraZeneca's newer cancer drugs are growing fast enough to offset older medicines losing sales to cheaper copies. That mix shift supports future revenue and gives management room to keep funding research and its drug pipeline.

Analyst inference

The beat was driven by oncology, rare disease and respiratory growth, while heart and diabetes drugs Farxiga and Brilinta shrank because of lost exclusivity, which means no more patent protection, and China procurement. Investors are rewarding growth in higher-priced specialty medicines over declining mass-market products.

Analyst inference

What to watch

1. Watch whether oncology keeps growing near 17%, since it is now 48% of product revenue and offsets Farxiga's 25% decline and Brilinta's exclusivity losses. Confirmed
2. Watch how management reshapes the business under its sustainable growth program, including whether cost savings are redirected into research rather than returned to shareholders. Proposed
3. Watch 2027 trial results, which the CEO says could be worth over $20 billion; success would extend the growth runway, while failures would leave a gap as older drugs shrink. Analyst inference

Evidence

• Original source link unavailable